Table 4

Procedural Characteristics

MT
(n = 44)
SAVR
(n = 52)
TAVR
(n = 108)
p Value
Crossover to TAVR3 (7)0 (0)NA
Crossover to SAVR0 (0)NA1 (1)
General anesthesiaNA52 (100)43 (40)<0.001
Procedure duration, minNA190.21 ± 47.7367.58 ± 38.86<0.001
Aortic valve intervention
 Balloon pre-dilationNA0 (0)99 (92)<0.001
 Medtronic CoreValveNA0 (0)63 (58)<0.001
 Edwards SAPIEN valveNA0 (0)43 (40)<0.001
 Symetis valveNA0 (0)2 (2)1.00
 Surgical bioprosthesisNA52 (100)1 (1)<0.001
 StentlessNA4 (8)0 (0)0.01
Revascularization7 (16)36 (69)39 (36)<0.001
 Vessel treated
 Left anterior descending artery6 (14)30 (58)26 (24)<0.001
 Left circumflex artery3 (7)24 (46)7 (7)<0.001
 Right coronary artery1 (2)24 (46)12 (11)<0.001
 Saphenous vein graft0 (0)0 (0)3 (3)0.255
 Complete revascularization0 (0)17 (35)8 (8)<0.001
 Residual SYNTAX score20.02 ± 18.59NA12.76 ± 14.260.019
 Percutaneous coronary intervention7 (16)1 (2)39 (36)<0.001
 Concomitant6 (14)0 (0)16 (15)0.014
 Staged1 (2)1 (2)23 (21)<0.001
 Coronary artery bypass graft0 (0)36 (69)0 (0)<0.001
Other concomitant interventions0 (0)10 (19)1 (1)<0.001
 Carotid endarterectomyNA1 (10)0 (0)
 Coronary endarterectomyNA2 (20)0 (0)
 Left atrial appendage occlusionNA4 (40)0 (0)
 Patent foramen ovale closureNA1 (10)1 (100)
 Pulmonary vein ablationNA1 (10)0 (0)
 Subvalvular myectomyNA1 (10)0 (0)
Hospital length of stay, days4.93 ± 5.5511.94 ± 4.578.48 ± 4.13<0.001

Values are mean ± SD with p values from analyses of variance or unpaired Student t tests or n (%) with p values using the Fisher exact or chi-square test.

NA = not available; other abbreviations as in Table 1.

  • Three patients assigned to medical therapy after heart team discussion subsequently crossed over to TAVR at 833 days (29-mm Medtronic CoreValve), at 25 days (26-mm Edwards SAPIEN XT valve), and at 493 days (29-mm Medtronic CoreValve) after initial medical therapy allocation.

  • Residual SYNTAX score has not been validated in post-CABG patients.